AndrewScottPaulsonMD

PubMed

• Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.
  Rona Yaeger, Nataliya V Uboha, Meredith S Pelster, Tanios S Bekaii-Saab, Minal Barve, Joel Saltzman, Joshua K Sabari, Julio A Peguero, Andrew Scott Paulson, Pasi A Jän...> ;Cancer Discovery. 2024 Apr 8
• 18 citations
  Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
  Dasari, A., Lonardi, S., Garcia-Carbonero, R., Elez, E., Yoshino, T., Sobrero, A., Yao, J., García-Alfonso, P., Kocsis, J., Cubillo Gracian, A., Sartore-Bianchi, A., S...> ;Lancet. 2023 Jul 1
• 5 citations
  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer.
  Kelly, R., Bever, K., Chao, J., Ciombor, K., Eng, C., Fakih, M., Goyal, L., Hubbard, J., Iyer, R., Kemberling, H., Krishnamurthi, S., Ku, G., Mordecai, M., Morris, V.,...> ;Journal for Immunotherapy of Cancer. 2023 Jun 1
• 25 citations
  Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-la...
  John H Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng, Eric Van Cutsem, Christina Wu, Andrew S Paulson, Joleen M Hubbard, Andrew L Coveler, Christ...> ;The Lancet. Oncology. 2023 May 1
• A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and...
  Arvind Dasari, Erika P Hamilton, Gerald S Falchook, Judy S Wang, Daneng Li, Max W Sung, Caly Chien, Shivani Nanda, Christopher Tucci, Marjo Hahka-Kemppinen, Andrew Sco...> ;Investigational New Drugs. 2023 Jun 1
• 12 citations
  Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase ...
  Fakih, M., Raghav, K., Chang, D., Larson, T., Cohn, A., Huyck, T., Cosgrove, D., Fiorillo, J., Tam, R., D'Adamo, D., Sharma, N., Brennan, B., Wang, Y., Coppieters, S.,...> ;Eclinicalmedicine. 2023 Apr 1
• 728 citations
  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
  Ghassan K. Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adria...> ;The Lancet. Oncology. 2020 May 1
• 1498 citations
  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;The Lancet. Oncology. 2018 Jul 1
• 223 citations
  Therapeutic advances in pancreatic cancer.
  Andrew Scott Paulson, Hop S. Tran Cao, Margaret A. Tempero, Andrew M. Lowy> ;Gastroenterology. 2013 May 1
• Join now to see all

Lectures

• Impact of gastric cancer treatment pathways on patient outcomes in a community oncology practice setting. 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020